RxDoctor Payments Data

Eugene Soroka, MD

Family Medicine · Port Hueneme, CANPI 1437109683

Payments from drug & device makers

$437,474in general payments, 2019–2025

Across 264 payments — averaging $1657.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$219K
  • Bayer$176K
  • Novo Nordisk AS$40K
  • Regeneron$2K
  • Novo Nordisk$161
  • Novartis$104
  • plus $244 from 4 others
$23,362in research payments, 2019–2025

Across 21 payments — averaging $1112.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$14K
  • American Regent$5K
  • Exact Sciences$4K
  • AbbVie$749

What the payments were for

  • Travel & lodging$96551%
  • Food & beverage$74840%
  • Education$1619%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$437,474 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$177,615
Medicare patients
361
Services billed
1,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$62,524
TrulicityDulaglutide51$62,260
JanuviaSitagliptin Phosphate98$52,361
XareltoRivaroxaban127$49,339
JardianceEmpagliflozin74$37,148
TradjentaLinagliptin46$19,120
RexultiBrexpiprazole16$17,703
MyrbetriqMirabegron28$17,068
RybelsusSemaglutide13$14,314
FarxigaDapagliflozin Propanediol40$12,208
LinzessLinaclotide16$12,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,241
Sevelamer Hcl12$9,254
Atorvastatin Calcium829$8,645
Fluticasone-VilanterolFluticasone/Vilanterol20$7,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$45$62,26051 claims
Johnson & JohnsonXarelto$72$49,339127 claims
Novo NordiskRybelsus$161$14,31413 claims
AbbVieLinzess$219,146$12,09316 claims
NovartisEntresto$104$5,84820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Port Hueneme

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →